INOVIO PHARMACEUTICALS, INC.
INO · XNASCIK 1055726fmd_0VCMFGAK6Z3ZS47GN79GCXBZKWManufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2026, 67 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 35 | 42 | 30 | 4 | 7 | 2 | 10 | 1 | 0 | 0 |
| Realized investment gains (losses) | – | (0) | (1) | 0 | (1) | – | – | – | – | – |
| Research and development | 89 | 99 | 95 | 88 | 94 | 249 | 188 | 87 | 76 | 54 |
| Total operating expenses | 112 | 126 | 125 | 115 | 131 | 303 | 278 | 145 | 113 | 87 |
| Operating income | (76) | (84) | (94) | (111) | (124) | (301) | (268) | (144) | (112) | (87) |
| Interest expense | – | 0 | 0 | 8 | 9 | 2 | 1 | 1 | 0 | 0 |
| Interest and investment income | 1 | 2 | 1 | – | – | – | – | 8 | 5 | 2 |
| Other non-operating income (expense) | – | (0) | (1) | 0 | (1) | 0 | (4) | (5) | (3) | (3) |
| Income before taxes | (74) | (88) | (95) | (121) | (163) | (303) | (278) | (135) | (107) | (85) |
| Income tax expense | 0 | 0 | 2 | (0) | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | (74) | (88) | (97) | (121) | (163) | (303) | (278) | (135) | (107) | (85) |
| Net income | (74) | (88) | (97) | (119) | (166) | (304) | (280) | (135) | (107) | (85) |
| Net income to common shareholders | (74) | (89) | (97) | (119) | – | – | – | – | – | – |